Encompass Health and Piedmont Healthcare announce joint venture to own and operate three inpatient rehabilitation hospitals in Georgia
News provided by
Share this article
Share this article
BIRMINGHAM, Ala. and ATLANTA, May 4, 2021 /PRNewswire/ Encompass Health Corp. (NYSE: EHC) and Piedmont Healthcare today announced they have executed a joint venture agreement to operate inpatient rehabilitation hospitals in Georgia. The parties are currently partnered on Regional Rehabilitation Hospital, in Phenix City, Alabama.
Piedmont logo
Recently, the partnership was granted certificates of need to own and operate new inpatient rehabilitation hospitals in Atlanta and Columbus, Georgia. In Columbus, the joint venture will construct a new 40-bed, freestanding inpatient rehabilitation hospital near the Piedmont Columbus Regional Northside Campus. The 40-bed Atlanta location will be built inside of the Piedmont Atlanta Hospital. Both new Georgia hospitals are expected to begin providing
Share this article
Share this article
ResearchAndMarkets.com s offering.
This report on the pharmaceutical excipient market covers an overview of excipients, the classification of excipients, and their significance in the pharmaceutical industry. A detailed analysis illustrating market dynamics, market structure analysis incorporating Porter s Five Force Framework analysis, and supply chain and distribution is discussed in detail. Excluded from the scope of this report is the use of excipients in cosmetics, food and beverage, and chemical industries. Emerging pharmaceutical excipients such as co-processed and multifunctional excipients and their impact on the future of the pharmaceutical excipients market are also analyzed.
Based on the type of material, the pharmaceutical excipients market is segmented into organic excipients, inorganic excipients and USP water. Based on route of administration, the pharmaceutical excipient market is segmented by oral, injectable/parenteral, top
/PRNewswire/ AllMed Healthcare Management, Inc., a leading provider of utilization management (UM) and independent review (IRO) services, today announced.
Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor
The clinical trials of KRAS G12C inhibitors are expected to enroll patients in the second half of 2021. Jacobio is aiming for the in-house combination therapy of KRAS G12C and SHP2 inhibitors. Inhibitors targeting KRAS G12D and KRAS G12V mutations have lead compounds.
News provided by
Share this article
Share this article
BEIJING and SHANGHAI and BOSTON, May 2, 2021 /PRNewswire/ Jacobio Pharmaceuticals (1167.HK) has announced the U.S. Food and Drug Administration (FDA) has approved company s Investigational New Drug (IND) application to develop a KRAS G12C inhibitor. IND application to the National Medical Products Administration (NMPA) in China was accepted on March 17. It will be used to treat advanced solid tumors with the KRAS G12C mutation, including but not limited to non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors. Patient enrollment for clinic
Terrabis Dispensary Opens First of Five Locations in Missouri
After much anticipation, the first Terrabis location will be opening in O Fallon, MO.
News provided by
Share this article
Share this article
O FALLON, Mo., May 3, 2021 /PRNewswire/ The Terrabis dispensary in O Fallon will open its doors on May 3rd, just shortly after the state of Missouri released medical marijuana sales data showing nearly $30 million since the market first launched in October. With over 90,000 patients, the state of Missouri is projected to reach $225 million to $300 million in 2021.
Serving the greater St. Charles County area, the new O Fallon dispensary is conveniently located at 1172 W. Terra Lane, right off of I-70, at Exit 216. The dispensary will open at 11 am. Specially trained staff will answer questions and assist patients.